Literature DB >> 17325219

Efficacy of the de novo-derived antimicrobial peptide WLBU2 against oral bacteria.

Karen F Novak1, William J Diamond, Sreenatha Kirakodu, Rebecca Peyyala, Kimberly W Anderson, Ronald C Montelaro, Timothy A Mietzner.   

Abstract

The efficacy of a novel synthetic antimicrobial peptide (WLBU2) was evaluated against three oral microorganisms (grown planktonically): Streptococcus gordonii, Fusobacterium nucleatum, and Porphyromonas gingivalis. WLBU2 killed all three species, with F. nucleatum being the most susceptible. WLBU2 also reduced the bacterial burden of S. gordonii and F. nucleatum biofilms.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17325219      PMCID： PMC1855554          DOI： 10.1128/AAC.00924-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Dental plaque formation.

Authors:  B Rosan; R J Lamont
Journal:  Microbes Infect       Date:  2000-11       Impact factor: 2.700

2.  De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity.

Authors:  Berthony Deslouches; Shruti M Phadke; Vanja Lazarevic; Michael Cascio; Kazi Islam; Ronald C Montelaro; Timothy A Mietzner
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease.

Authors:  H J Rupprecht; S Blankenberg; C Bickel; G Rippin; G Hafner; W Prellwitz; W Schlumberger; J Meyer
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

4.  Novel antimicrobial peptides derived from human immunodeficiency virus type 1 and other lentivirus transmembrane proteins.

Authors:  S B Tencza; J P Douglass; D J Creighton; R C Montelaro; T A Mietzner
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.

Authors:  Berthony Deslouches; Kazi Islam; Jodi K Craigo; Shruti M Paranjape; Ronald C Montelaro; Timothy A Mietzner
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein.

Authors:  M A Miller; M W Cloyd; J Liebmann; C R Rinaldo; K R Islam; S Z Wang; T A Mietzner; R C Montelaro
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

7.  Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels.

Authors:  J Zhu; A A Quyyumi; J E Norman; G Csako; M A Waclawiw; G M Shearer; S E Epstein
Journal:  Am J Cardiol       Date:  2000-01-15       Impact factor: 2.778

8.  Impact of infectious burden on extent and long-term prognosis of atherosclerosis.

Authors:  Christine Espinola-Klein; Hans J Rupprecht; Stefan Blankenberg; Christoph Bickel; Helmuth Kopp; Gerd Rippin; Anja Victor; Gerd Hafner; Wolfgang Schlumberger; Jürgen Meyer
Journal:  Circulation       Date:  2002-01-01       Impact factor: 29.690

9.  Potentially modifiable risk factors for dementia in identical twins.

Authors:  Margaret Gatz; James A Mortimer; Laura Fratiglioni; Boo Johansson; Stig Berg; Chandra A Reynolds; Nancy L Pedersen
Journal:  Alzheimers Dement       Date:  2006-04       Impact factor: 21.566

10.  Radiographic measures of chronic periodontitis and carotid artery plaque.

Authors:  Steven P Engebretson; Ira B Lamster; Mitchell S V Elkind; Tatjana Rundek; Neill J Serman; Ryan T Demmer; Ralph L Sacco; Panos N Papapanou; Moïse Desvarieux
Journal:  Stroke       Date:  2005-02-03       Impact factor: 7.914
View more
  6 in total

1.  Bioactivity of WLBU2 peptide antibiotic in combination with bioerodible polymer.

Authors:  J R McClanahan; R Peyyala; R Mahajan; R C Montelaro; K F Novak; D A Puleo
Journal:  Int J Antimicrob Agents       Date:  2011-09-15       Impact factor: 5.283

2.  WLBU2 Antimicrobial Peptide as a Potential Therapeutic for Treatment of Resistant Bacterial

Authors:  Lina Elsalem; Ayat Khasawneh; Suhaila Al Sheboul
Journal:  Turk J Pharm Sci       Date:  2022-02-28

3.  Synergism between WLBU2 peptide and antibiotics against methicillin-resistant Staphylococcus aureus and extended-spectrum beta-lactamase-producing Enterobacter cloacae.

Authors:  Lina Elsalem; Suhaila Al Sheboul; Ayat Khasawneh
Journal:  J Appl Biomed       Date:  2021-01-18       Impact factor: 1.797

4.  Evaluation of WLBU2 peptide and 3-O-octyl-sn-glycerol lipid as active ingredients for a topical microbicide formulation targeting Chlamydia trachomatis.

Authors:  M C Skinner; A O Kiselev; C E Isaacs; T A Mietzner; R C Montelaro; M F Lampe
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

Review 5.  Beyond conventional antibiotics - New directions for combination products to combat biofilm.

Authors:  Danir Fanisovich Bayramov; Jennifer Ann Neff
Journal:  Adv Drug Deliv Rev       Date:  2016-08-03       Impact factor: 15.470

6.  Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia.

Authors:  Hiroyuki Wakabayashi; Koji Yamauchi; Tetsuo Kobayashi; Tomoko Yaeshima; Keiji Iwatsuki; Hiromasa Yoshie
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.